House Subcommittee Approves $2.1 Billion for FDA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

House Subcommittee Approves $2.1 Billion for FDA


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (June 26)—The US Food and Drug Administration will have a $2.1 billion budget next year if the fiscal year 2009 bill markup by the US House of Representatives’ Agriculture Appropriations Subcommittee passes through Congress. The subcommittee approved for FDA $282 million above the President’s budget request for FY 2009.

In her opening statement at last week’s meeting, Subcommittee Chairwoman Rosa DeLauro (D-CT) noted that the administration had recently made a request for an additional $275 million for FDA [see full story]. “To be sure, this is a long overdue acknowledgment that the status quo is not working when it comes to our broken food safety system,” she said. “So we are indeed, eager to fully fund that request and provide the critical resources necessary for reform.”

DeLauro added her concern that the administration has yet to indicate how FDA should use these additional funds. “…Real reform requires real management – so this committee will convene hearings and require spending reports to ensure the money is used as effectively as possible,” she said.

The marked-up Subcommittee bill goes to the House Appropriations Committee next where it will be further reviewed and marked up before going to the full House of Representatives.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here